Literature DB >> 25827099

Development and Use of Disease-Specific (Reference) Models for Economic Evaluations of Health Technologies: An Overview of Key Issues and Potential Solutions.

Gerardus W J Frederix1, Hossein Haji Ali Afzali, Erik J Dasbach, Robyn L Ward.   

Abstract

Mesh：

Year:  2015        PMID： 25827099     DOI： 10.1007/s40273-015-0274-y

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  24 in total

Review 1.  OMERACT 6 Economics Working Group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis.

Authors:  Sherine Gabriel; Michael Drummond; Andreas Maetzel; Maarten Boers; Doug Coyle; Vivian Welch; Peter Tugwell
Journal:  J Rheumatol       Date:  2003-04       Impact factor: 4.666

2.  Archimedes: a trial-validated model of diabetes.

Authors:  David M Eddy; Leonard Schlessinger
Journal:  Diabetes Care       Date:  2003-11       Impact factor: 19.112

Review 3.  Towards a reference case for use in future economic evaluations of interventions in osteoarthritis.

Authors:  Michael Drummond; Andreas Maetzel; Sherine Gabriel; Lyn March
Journal:  J Rheumatol Suppl       Date:  2003-12

Review 4.  Characterizing structural uncertainty in decision analytic models: a review and application of methods.

Authors:  Laura Bojke; Karl Claxton; Mark Sculpher; Stephen Palmer
Journal:  Value Health       Date:  2009 Jul-Aug       Impact factor: 5.725

5.  Addressing the challenge for well informed and consistent reimbursement decisions: the case for reference models.

Authors:  Hossein Haji Ali Afzali; Jonathan Karnon
Journal:  Pharmacoeconomics       Date:  2011-10       Impact factor: 4.981

6.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.

Authors:  Don Husereau; Michael Drummond; Stavros Petrou; Chris Carswell; David Moher; Dan Greenberg; Federico Augustovski; Andrew H Briggs; Josephine Mauskopf; Elizabeth Loder
Journal:  Pharmacoeconomics       Date:  2013-05       Impact factor: 4.981

7.  A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68).

Authors:  P M Clarke; A M Gray; A Briggs; A J Farmer; P Fenn; R J Stevens; D R Matthews; I M Stratton; R R Holman
Journal:  Diabetologia       Date:  2004-10-27       Impact factor: 10.122

8.  Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting.

Authors:  Stavros Petrou; Alastair Gray
Journal:  BMJ       Date:  2011-04-11

9.  Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting.

Authors:  Andrew J Palmer; Philip Clarke; Alastair Gray; Jose Leal; Adam Lloyd; David Grant; James Palmer; Volker Foos; Mark Lamotte; William Hermann; Jacob Barhak; Michael Willis; Ruth Coleman; Ping Zhang; Phil McEwan; Jonathan Betz Brown; Ulf Gerdtham; Elbert Huang; Andrew Briggs; Katarina Steen Carlsson; William Valentine
Journal:  Value Health       Date:  2013-04-18       Impact factor: 5.725

10.  Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7.

Authors:  David M Eddy; William Hollingworth; J Jaime Caro; Joel Tsevat; Kathryn M McDonald; John B Wong
Journal:  Med Decis Making       Date:  2012 Sep-Oct       Impact factor: 2.583
View more
  3 in total

Review 1.  Verification of Decision-Analytic Models for Health Economic Evaluations: An Overview.

Authors:  Erik J Dasbach; Elamin H Elbasha
Journal:  Pharmacoeconomics       Date:  2017-07       Impact factor: 4.981

Review 2.  Transparency in Decision Modelling: What, Why, Who and How?

Authors:  Christopher James Sampson; Renée Arnold; Stirling Bryan; Philip Clarke; Sean Ekins; Anthony Hatswell; Neil Hawkins; Sue Langham; Deborah Marshall; Mohsen Sadatsafavi; Will Sullivan; Edward C F Wilson; Tim Wrightson
Journal:  Pharmacoeconomics       Date:  2019-11       Impact factor: 4.981

3.  Check Your Checklist: The Danger of Over- and Underestimating the Quality of Economic Evaluations.

Authors:  Geert W J Frederix
Journal:  Pharmacoecon Open       Date:  2019-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.